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Sex Med 2Introduction: Short-term data on the effect of low-intensity extracorporeal shockwave therapy (Li-ESWT) on
erectile dysfunction (ED) have been inconsistent. The suggested mechanisms of action of Li-ESWT on ED
include stimulation of cell proliferation, tissue regeneration, and angiogenesis, which can be processes with a long
generation time. Therefore, long-term data on the effect of Li-ESWT on ED are strongly warranted.
Aim: To assess the outcome at 6 and 12 months of linear Li-ESWT on ED from a previously published ran-
domized, double-blinded, sham-controlled trial.
Methods: Subjects with ED (N ¼ 126) who scored lower than 25 points in the erectile function domain of the
International Index of Erectile Function (IIEF-EF) were eligible for the study. They were allocated to 1 of 2
groups: 5 weekly sessions of sham treatment (group A) or linear Li-ESWT (group B). After a 4-week break, the 2
groups received active treatment once a week for 5 weeks. At baseline and 6 and 12 months, subjects were
evaluated by the IIEF-EF, the Erectile Hardness Scale (EHS), and the Sexual Quality of Life in Men.
Main Outcome Measures: The primary outcome measure was an increase of at least 5 points in the IIEF-EF
(DIIEF-EF score). The secondary outcome measure was an increase in the EHS score to at least 3 in men with a
score no higher than 2 at baseline. Data were analyzed by linear and logistic regressions.
Results: Linear regression of the DIIEF-EF score from baseline to 12 months included 95 patients (dropout
rate ¼ 25%). Adjusted for the IIEF-EF score at baseline, the difference between groups B and A was1.30 (95%
CI ¼ 4.37 to 1.77, P ¼ .4). The success rate based on the main outcome parameter (DIIEF-EF score  5) was
54% in group A vs 47% in group B (odds ratio ¼ 0.67, P ¼ .28). Improvement based on changes in the EHS
score in groups A and B was 34% and 24%, respectively (odds ratio ¼ 0.47, P ¼ .82).
Conclusion: Exposure to 2 cycles of linear Li-ESWT for ED is not superior to 1 cycle at 6- and 12-month
follow-ups. Fojecki GL, Tiessen S, Osther PJS. Effect of Linear Low-Intensity Extracorporeal Shockwave
Therapy for Erectile Dysfunction—12-Month Follow-Up of a Randomized, Double-Blinded, Sham-
Controlled Study. Sex Med 2018;6:1e7.
Copyright  2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Restoration of natural erection is the ultimate goal of erectile
dysfunction (ED) therapy.1 The introduction of phosphodies-
terase type 5 inhibitors (PDE5is) in the late 1990s completely
changed the treatment scenario of ED; however, this treatment
modality does not represent a cure. Furthermore, most oral
medications require planning of sexual intercourse and are
associated with, for example, headache, dizziness, or decrease in
blood pressure, which can have serious consequences, especially
in combination with nitrate preparations.2,31
Table 1. Inclusion and exclusion criteria
Inclusions Age > 40 y
Complaining of ED > 6 mo
In stable relationship (>3 mo)
Exclusions Surgery or radiotherapy of pelvic region
Treatment with anticoagulants (except
acetylsalicylic acid 75 mg)
Treatment with antiandrogens
Anatomic penile deformations or penile prosthesis
Total testosterone level < 8 nmol/dl
Serious heart or lung disease
Psychiatric or neurologic disorder
Pregnant partner
IIEF-EF score  25
ED ¼ erectile dysfunction; IIEF-EF ¼ International Index for Erectile Function
erectile function domain.
2 Fojecki et alPenile low-intensity extracorporeal shockwave therapy
(Li-ESWT) was previously reported to be capable of curing
ED.4,5 The underlying mechanisms of action remain elusive.
Potential beneﬁcial effects related to ED include stimulation of
cell proliferation, tissue regeneration, and angiogenesis.5 In a
diabetic rat model, Li-ESWT was shown to promote regener-
ation of neuronal nitric oxide synthaseepositive nerves, endo-
thelium, and smooth muscle cells.6 The effect seemed to be
mediated by the recruitment of endogenous mesenchymal stem
cells.6 In addition, Li-ESWT showed potential in promoting
angiogenesis in a pelvic neurovascular injury rat model.7
Human clinical trials of Li-ESWT have produced inconsistent
results.8e16 A recent systematic review and meta-analysis
concluded that Li-ESWT might be especially suitable for men
with mild ED5; yet 1 of the included trials only implicated a
potential value for severe ED.11 In addition, in several of the
trials, an inconsistency was reported of ED outcome measures
after Li-ESWT—International Index of Erectile Function (IIEF)
vs Erectile Hardness Scale (EHS)—which are difﬁcult to
explain.17 One reason for the conﬂicting results might be that the
potential of the Li-ESWTeinduced tissue regeneration and
angiogenesis, which are inherently slow biological processes,
might not have reached its maximum at time of analysis. Thus,
the effect of nerve regeneration and angiogenesis on ED might
have considerable interindividual variance, and therefore long-
term data on the effect of Li-ESWT on ED could better eluci-
date statistical intervariance.4,5,17
In this article, we report on outcomes at 6- and 12-month
follow-up from a previously published randomized, sham-
controlled clinical trial on linear Li-ESWT (LLi-ESWT) for ED.15
The objective of the study was to evaluate the effects of LLi-
ESWT on ED assessed by the IIEF-EF, EHS, and Sexual
Quality of Life in Men (SQoL-M) questionnaires.
The hypothesis of the study was that LLi-ESWT would
improve erectile function at 6 and 12 months, possibly through
regenerative processes and angiogenesis.Figure 1. Study design. EHS ¼ Erectile Hardness Scale; IIEF ¼
International Index for Erectile Function; LLi-ESWT ¼ linear low-
energy extracorporeal shockwave therapy; SQoL-M ¼ Sexual
Quality of Life for Man.METHODS
Details of the trial (NCT02063061), in which short-term data
were reported, were previously published.15 Participants under-
went a standard assessment that included medical history,
physical examination, and blood testing. Subjects with vasculo-
genic ED were selected based on inclusion and exclusion criteria
(Table 1). Use of any erectogenic therapy was restricted during
treatment and short-term follow-up. Furthermore, in subjects
previously treated for ED, a 4-week washout period was
implemented.
The study was carried out from February through August
2014 at the Department of Urology at the Hospital of Southern
Jutland (Sønderborg, Denmark). This department offers primary
urologic care to almost 250,000 inhabitants within a 100-km
range.The research secretary generated a random list (www.
randomisation.org) with a 1:1 ratio. 126 subjects were allocated
to group A or B. The manufacturer of the ESWT device (Richard
Wolf GmbH, Knittlingen, Germany) provided 3 identically
looking gel pads that were specially designed for this study. In the
1st phase of treatment, a non-penetrable active gel pad was used.
Pads were marked A or B, which corresponded to the sham or
active group. In the 2nd phase of the trial, all patients received
LLi-ESWT using another active gel pad. It had an outer design
identical to those used during the 1st phase, allowing for concealed
group allocation during the entire study period for investigator
and patients. Participants received 5 weekly treatment sessions of
LLi-ESWT or sham. After a 4-week break, the 2 groups received
LLi-ESWT. We imitated the crossover design from pharmaco-
logic studies. We chose to treat all subjects in the 2nd phase
because we expected that treatment would have a prolonged effect.
A summary of the study is presented in Figure 1.
The primary outcome measure was the change in IIEF-EF
score from baseline to after 6 or 12 months (DIIEF-EF). To
enable comparison of our ﬁndings with results of other
trials,11,12,16 changes in IIEF-EF score of at least 5 points were
considered clinically relevant. Secondarily, we looked for changes
in the EHS score in which an increase to at least 3 indicated
improvement. Changes in SQoL-M score from baseline to ﬁnal
follow-up assessment also were recorded. Use of additional
pharmacologic treatment for ED was controlled using a national
prescription database, which is an online platform that enablesSex Med 2018;6:1e7
Effect of Linear Li-ESWT on ED 3physicians to prescribe medicine and monitor whether patients
picked up potency enhancers from the pharmacy.
Treatment sessions consisted of 600 shockwave (SW) pulses
with an energy ﬂux density (EFD) of 0.09 mJ/mm2 and a
frequency of 5 Hz delivered within 15 minutes. SWs were given
in 3 areas: 300 impulses were administered to the corpora
cavernosa in the upright position and 150 impulses were
administered to each penile crus in the lithotomy position. The
ESWT device was equipped with a piezoelectric linear therapy
source (FBL10; Richard Wolf GmbH). Penetration depth in
this device is adjusted by applying different gel pads. In our
study we used a 0-mm gel pad that allowed treatment of an
organ area 1 cm deep and 5 cm wide. The number of impulses
used was chosen based on a previous trial reporting positive
outcomes after applying focused Li-ESWT, taking into
consideration that a linear probe delivers SWs to a wider area of
the penis.9
Outcomes were assessed using questionnaires (IIEF-EF, EHS,
and SQoL-M) at baseline and at 6 and 12 months. Before the 1st
treatment session, subjects completed questionnaires on a tablet
in a separate room and the research nurse assisted on request.
During follow-up, patients received an e-mail with a link that
allowed them to submit questionnaires from their own electronic
devices at home. All questionnaires had an identical form and
layout. Answers were collected on a server (www.surveyexact.dk).
Subjects who did not have access to a computer (n ¼ 21)
received questionnaires sent by mail with a return envelope. The
investigator with the assistance of a secretary transferred those
results to the server.
The project was registered at www.clinicaltrials.gov
(NCT02063061). The study was approved by the regional
ethics committee (ID-20120028), the Danish Ministry of
Health (2013073909; CIV-13-07-011546), and the Regional
Data Protection Agency. The Good Clinical Practice unit at the
University of Southern Denmark monitored the complete
research process. The investigator acquired written informed
consent before the study.Statistics Including Power of Study
We included 63 patients in each group, which was required to
detect a minimum 5-point change in IIEF-EF score as the pri-
mary end point. We assumed a type 1 error of 5%, power of
80%, and common SD of 9.3. We expected 10% dropouts.
Outcome measurements were summarized at baseline and 6
months and 12 months after completing the treatment protocol.
We present our results as the number of subjects, means, SDs,
and 95% CIs. The change from baseline to 12 months was
compared between groups using linear regression adjusting for
baseline measurements. Adherence to the normality assumption
was checked by visual inspection of QQ plots. The change from
baseline over time was analyzed by a mixed-effects linear
regression with random effects given by the patients and inter-
action with time. A P value less than 0.05 was consideredSex Med 2018;6:1e7signiﬁcant. Statistical analysis was performed with STATA 14
(StataCorp, College Station, TX, USA).RESULTS
From February through May 2014, we screened 184 patients.
126 participants were found eligible for the study and random-
ized in 2 groups at the ratio of 1:1. Baseline characteristics are
presented in Table 2.
43 subjects (68%) from group A (sham; LLI-ESWT 5 times)
and 52 (82%) from group B (LLI-ESWT 10 times) completed the
questionnaires 6 and 12months after treatment. Patients whowere
found ineligible after randomization (IIEF-EF score> 25, n¼ 4),
those who dropped out during treatment phase (n¼ 4), and those
who did not return questionnaires (n ¼ 23) were excluded from
ﬁnal analysis. A ﬂowchart presenting the inclusion process,
according to the Consolidated Standards of Reporting Trials
(CONSORT) statement,18 is shown in Figure 2.
Mean IIEF-EF scores in group B were 10.9 (SD ¼ 7.1) at
baseline 13.5 (SD ¼ 9.2) at 6 months, and 12.8 (SD ¼ 9.4) at
12 months. Mean scores in group A were 11.2 (SD ¼ 6.6), 16
(SD ¼ 9.8), and 14.3 (SD ¼ 9.9), respectively. Results at 4-week
follow-up after 5 sham treatment sessions (group A) from a
previously published article15 are presented in Figure 3. Linear
regression of DIIEF-EF score from baseline to 12 months
included 95 patients. Adjusting for IIEF-EF score at baseline, the
difference between groups B and A was 1.30 (CI ¼ 4.37 to
1.77, P ¼ .4). The success rate based on the main outcome
parameter (DIIEF-EF  5) was 54% in group A vs 47% in group
B (odds ratio ¼ 0.67, P ¼ .28). The improvement based on
changes in EHS score in groups A and B was 34% and 24%,
respectively (odds ratio ¼ 0.47, P ¼ .82).
Analysis of IIEF-EF changes over time showed a signiﬁcant
increase from baseline only in group A (P ¼ .001); however, it
should be noted that it did not reach the predeﬁned minimal
clinically important difference. The difference between groups
was not signiﬁcant (P ¼ .18).
The values of SQoL-M were 37% in group A and 35% in
group B at 1-year follow-up. The change from baseline
was 6.1% in group A and 6.6% in group B (P ¼ .82).
Adjusting for use of erectogenic drugs did not result in any
statistically signiﬁcant differences between groups. Mean IIEF-
EF scores in group A were 11.4 (95% CI ¼ 7.8e15) at base-
line, 10.9 (95% CI ¼ 7e14.8) at 6 months, and 9.5 (95% CI ¼
6e13) at 12 months. Corresponding results in group B were
12.9 (95% CI ¼ 9.5e16.3), 13.1 (95% CI ¼ 8.4e17.8), and
12.6 (95% CI ¼ 8.4e16.8).Safety
We did not see any serious adverse events of LLi-ESWT during
treatment or follow-up. One patient from group A was diagnosed
with Peyronie disease (PD) 6 months after the treatment.
Table 2. Patients’ basic characteristics
Population (N ¼ 126) Group A (n ¼ 43) Group B (n ¼ 52)
Age (y) 64.9 (10.5) 64.4 (8.3) 66.8 (8.2)
BMI (kgm2) 27.4 (3.6) 27.6 (3.1) 27.3 (3.8)
Total testosterone (nmol/dL) 14.0 (4.4) 13.1 (4.1) 14.4 (4.9)
Smoking status 22 (17.5%) 12 (27.9%) 6 (10.9%)
Myocardial infarction 15 (11.9%) 6 (13.9%) 5 (11.7%)
Hypercholesterolemia 93/54* (73.8%) 33/20* (76.7%) 35/22* (67.3%)
Peripheral artery disease 11 (8.7%) 2 (4.6%) 8 (15%)
Hypertension 54 (42.8%) 15 (34.9%) 22 (42.3%)
Diabetes 15 (11.9%) 7 (16.3%) 3 (5.8%)
Treatment with PDE5i — 24 (56%) 30 (58.0%)
BMI ¼ body mass index; PDE5i ¼ phosphodiesterase type 5 inhibitor.
*Diagnosed during screening.
4 Fojecki et alUsing a national prescription database to assess the number of
patients who were taking medications for ED during follow-up,
we found that 24 men (56%) in group A and 30 men (58%) in
group B were using a PDE5i and 1 man (2%) in group B was
injecting alprostadil.DISCUSSION
There is an imperative requirement for more long-term data on
the effect of Li-ESWT on ED.4,5,17 In this report we present 6-
and 12-month data from a randomized, sham-controlled trial on
LLi-ESWT for ED. In line with our previously published short-
term results,15 we did not ﬁnd a clinically signiﬁcant effect of
LLI-ESWT on ED at our time points. 2 controlled trials onFigure 2. Patient ﬂow diagram. DRE ¼ digital rectal examination; I
domain.Li-ESWT reporting long-term data on ED have been pub-
lished.12,16 Srini et al16 reported on 12-month follow-up after
focused Li-ESWT and found signiﬁcant increases in the IIEF-EF
and EHS domains. However, these results are seriously ﬂawed by
a very high dropout rate (58% and 42% in sham and active
treated groups, respectively) and therefore should be interpreted
with caution. Olsen et al,12 who initially reported positive short-
term results of focused LI-ESWT in the EHS but not in the
IIEF-EF domain, found no signiﬁcant effects at 6 months for
either outcome measure. Thus, the overall long-term clinical ef-
fects of Li-ESWT, whether focused or linear SW delivery, seem to
be doubtful. Indeed, there is reason to doubt the short-term
clinical effects of Li-ESWT, because results from randomized
trials have been inconsistent, and only 1 of 3 systematic reviewsIEF-EF ¼ International Index for Erectile Function erectile function
Sex Med 2018;6:1e7
Figure 3. Predicted change of International Index for Erectile
Function erectile function domain score (mean and 95% CI) over
time. SHAM ¼ effect assessed 4 weeks after 5 simulated treat-
ment sessions.
Effect of Linear Li-ESWT on ED 5and meta-analyses on Li-ESWT for ED has documented increases
in IIEF-EF4,5,19 to what is considered the minimal clinically
important difference (DIIEF-EF score > 4).20 Whether repeated
treatment sessions over a longer period might stimulate cellular
and molecular mechanisms, which are believed to be involved in
angiogenesis and nerve regeneration translating into signiﬁcant
clinical effects, still needs to be evaluated in controlled trials.
Treatment with LLi-ESWT in 2 5-week sessions with a 4-week
break (group B) did not result in any positive improvements in
IIEF-EF, EHS, or SQoL-M scores. In fact, group A, which
received only 5-week treatment, had a better outcome during
follow-up, although not reaching the predeﬁned clinically relevant
end point (DIIEF-EF  5), suggesting that extending treatment
sessions beyond 5 weeks might not achieve superior results.
There could be several reasons for the conﬂicting results on the
effect of Li-ESWT in the literature. Among these are differences
in SW technology (piezoelectric, electromagnetic, electrohy-
draulic), differences in SW delivery (focused, linear), and dif-
ferences in number of SWs used, which potentially confuse
comparison of studies and thus lower the validity of meta-
analyses. In our study the number of SWs delivered with the
linear probe was calculated based on data from a previous trial
using focused ESWT9 with an identical EFD (0.09 mJ/mm2).
There are several reports of positive outcomes of LLi-ESWT
for ED.14,21e23 3 trials applied an electromagnetic device
(Renova, Direx Systems GmbH, Wiesbaden, Germany).21e23
Bechara et al21 and Reisman et al22 treated their patients with
3,600 SWs and an EFD of 0.09 mJ/mm2 in 4 weeks, and
Pelayo-Nieto et al23 applied the same energy level but their
treatment protocol consisted of 4 treatments of 5,000 SWs.
Motil and Sramkova14 tested the same piezoelectric therapy
source used in the present study. Their treatment protocol
involved 4 weekly sessions of 4,000 SWs, an EFD of 0.16 mJ/
mm2, and a penetration depth of 10 to 15 mm. Positive clinicalSex Med 2018;6:1e7effects were reported in all cited trials; however, only the study of
Bechara et al21 was designed as a randomized controlled trial and
the others were open-label trials.14,22,23 Considering those
encouraging outcomes and absence of serious adverse effects, it
seems safe to proceed with planning LLi-ESWT trials using a
larger number of SWs. The advantage of linear ESWT is that
usage of the linear probe delivers SWs to a wider area of the
corpora cavernosa, thus limiting movements of the probe during
treatment compared with focused ESWT, which could decrease
user dependency.14 However, before clinical trials on ESWT in
ED are performed, dose-ﬁnding studies deﬁning the right pro-
tocol settings for the speciﬁc device tested should be mandatory,
which to a large extent has been neglected in previous trials
including ours. Recommending Li-ESWT as a treatment option
for ED needs to be properly scientiﬁcally evaluated, because
offering the treatment without evidence carries serious ethical
issues.24
In general, health care professionals should be aware that ED
might be an indicator of endothelial dysfunction that precedes
vascular events.25 Therefore, when applicable, lifestyle changes
should always be recommended to decrease vascular risk factors,
which have been shown to improve IIEF-EF score.26,27Limitations
We estimated treatment dose based on the trial of Vardi
et al,9 in which a focused transducer was used. In our trial
we used a linear probe, and the lack of a dose-ﬁnding study
can be considered a limitation of our study. Furthermore,
owing to our study design, we could assess only short-term
effects of sham treatment, because all participants received
active treatment in the 2nd phase. Results obtained 4 weeks
after 5 simulated treatment sessions (sham) served as a
control.
In our short-term data we had a very low dropout rate (3%).15
In the present report, 25% of patients were lost to follow-up,
which might have introduced selection bias.28 The difference
in dropout rate between groups A (32%) and B (17%) might
explain the better outcome in patients who received only 5
treatment sessions (group A), because an uneven dropout can
introduce potential bias favoring positive outcomes.29 Further-
more, a larger proportion of men in group B complained of
peripheral artery disease, which could be indicative of more se-
vere endothelial dysfunction, and thus they would be expected to
have a poorer response. Differences in tobacco usage and prev-
alence of diabetes between the 2 groups also could have affected
the outcome.
We did not apply objective measures for diagnosis of ED
etiology. Usage of duplex ultrasonography to conﬁrm vascular
insufﬁciency for patient selection might have resulted in a
different outcome.
The gel pad applied in our study was originally developed for
treatment of skin wounds. In this conﬁguration, some of the
6 Fojecki et alacoustic energy is restricted to the transducer and thus might not
be effectively transmitted to the site of need. Different gel pad
designs might be more effective, and in future studies a greater
penetration depth of SWs could be a target of interest.
Results of previous trials9,12,14 suggested that PDE5i re-
sponders showed signiﬁcantly improved erectile function. Our
trial was not speciﬁcally powered to make distinctions between
PDE5i responders and non-responders.Safety
There has been concern that repeated Li-ESWT treatments can
result in ﬁbrosis of the corpora cavernosa and eventually the
development of PD.30 In our series 1 patient developed PD with
classic plaques and 30 angulation 6 months after treatment. The
patient was in group A, meaning that he received ESWT only
during the 2nd round of treatment. Men in group B, who received
2 rounds of ESWT, had no long-term complaints, suggesting that
the case of PD was coincidental and not related to the SW effects.Strengths
Using a national prescription database, we could reliably
identify patients who were using pharmacologic treatment for
ED during the follow-up period. The proportion of men using
medication for ED during follow-up was comparable between
groups. During the complete trial, data collection and manage-
ment were monitored by an independent Good Clinical Practice
unit, which also could be considered a strength of the study.CONCLUSION
This study showed that 2 cycles of LLi-ESWT for ED (10
treatment sessions) were not superior to 1 cycle (5 sessions) at 6- and
12-month follow-up.Targets for future Li-ESWT research could be
increasing the penetration depth and the number of SWs. Because
the effect of Li-ESWT on ED is questionable, treatment of patients
with ED with this therapeutic modality preferably should be
conﬁned to controlled clinical trials.
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